Folgen
Asger Bihlet
Asger Bihlet
Chief Scientific Officer, NBCD
Bestätigte E-Mail-Adresse bei nbcd.com
Titel
Zitiert von
Zitiert von
Jahr
Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future
MA Karsdal, M Michaelis, C Ladel, AS Siebuhr, AR Bihlet, JR Andersen, ...
Osteoarthritis and cartilage 24 (12), 2013-2021, 2016
3672016
Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial
MC Hochberg, A Guermazi, H Guehring, A Aydemir, S Wax, ...
Jama 322 (14), 1360-1370, 2019
2792019
Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials
MA Karsdal, I Byrjalsen, P Alexandersen, A Bihlet, JR Andersen, BJ Riis, ...
Osteoarthritis and cartilage 23 (4), 532-543, 2015
1552015
A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in …
K Henriksen, I Byrjalsen, JR Andersen, AR Bihlet, LA Russo, ...
Bone 91, 122-129, 2016
922016
Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD
AR Bihlet, MA Karsdal, JMB Sand, DJ Leeming, M Roberts, W White, ...
Respiratory Research 18, 1-11, 2017
782017
OA phenotypes, rather than disease stage, drive structural progression–identification of structural progressors from 2 phase III randomized clinical studies with symptomatic …
MA Karsdal, A Bihlet, I Byrjalsen, P Alexandersen, C Ladel, M Michaels, ...
Osteoarthritis and cartilage 23 (4), 550-558, 2015
762015
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study
F Eckstein, MC Hochberg, H Guehring, F Moreau, V Ona, AR Bihlet, ...
Annals of the Rheumatic Diseases 80 (8), 1062-1069, 2021
712021
High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD–results from the ECLIPSE study
JMB Sand, DJ Leeming, I Byrjalsen, AR Bihlet, P Lange, R Tal-Singer, ...
Respiratory research 17, 1-12, 2016
702016
The impact of clinical trial monitoring approaches on data integrity and cost—a review of current literature
R Olsen, AR Bihlet, F Kalakou, JR Andersen
European journal of clinical pharmacology 72, 399-412, 2016
682016
Impact of source data verification on data quality in clinical trials: an empirical post hoc analysis of three phase 3 randomized clinical trials
JR Andersen, I Byrjalsen, A Bihlet, F Kalakou, HC Hoeck, G Hansen, ...
British journal of clinical pharmacology 79 (4), 660-668, 2015
582015
Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis
AR Bihlet, I Byrjalsen, AC Bay-Jensen, JR Andersen, C Christiansen, ...
Arthritis research & therapy 21, 1-10, 2019
482019
Protein biomarkers associated with pain mechanisms in osteoarthritis
CS Thudium, H Löfvall, MA Karsdal, AC Bay-Jensen, AR Bihlet
Journal of proteomics 190, 55-66, 2019
382019
OP0059 Efficacy and safety of intra-articular sprifermin in symptomatic radiographic knee osteoarthritis: pre-specified analysis of 3-year data from a 5-year randomised …
M Hochberg, A Guermazi, H Guehring, A Aydemir, S Wax, ...
Annals of the Rheumatic Diseases 77 (Suppl 2), 80-81, 2018
35*2018
The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial
H Guehring, F Moreau, B Daelken, C Ladel, O Guenther, AR Bihlet, ...
Seminars in Arthritis and Rheumatism 51 (2), 450-456, 2021
312021
Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis
AC Bay-Jensen, A Bihlet, I Byrjalsen, JR Andersen, BJ Riis, ...
Scientific reports 11 (1), 6583, 2021
282021
Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase …
EGB Vijverberg, TM Axelsen, AR Bihlet, K Henriksen, F Weber, K Fuchs, ...
Alzheimer's research & therapy 13, 1-8, 2021
232021
Matrix metalloproteinase mediated type I collagen degradation is an independent predictor of increased risk of acute myocardial infarction in postmenopausal women
DM Bertelsen, JS Neergaard, CL Bager, SH Nielsen, NH Secher, ...
Scientific reports 8 (1), 5371, 2018
232018
Clinical and biochemical factors associated with risk of total joint replacement and radiographic progression in osteoarthritis: data from two phase III clinical trials
AR Bihlet, JJ Bjerre-Bastos, JR Andersen, I Byrjalsen, MA Karsdal, ...
Seminars in Arthritis and Rheumatism 50 (6), 1374-1381, 2020
222020
Biomarkers of collagen turnover are related to annual change in FEV1 in patients with chronic obstructive pulmonary disease within the ECLIPSE study
DJ Leeming, I Byrjalsen, JMB Sand, AR Bihlet, P Lange, R Thal-Singer, ...
BMC pulmonary medicine 17, 1-10, 2017
222017
Clinical drug development using dynamic biomarkers to enable personalized health care in COPD
AR Bihlet, MA Karsdal, AC Bay-Jensen, S Read, JH Kristensen, ...
Chest 148 (1), 16-23, 2015
212015
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20